Objective: Trousseau's syndrome, malignancy associated hypercoagulability, comprises polymorphic spectrum of arterial and venous thrombotic disorders in setting of neoplastic disease. We suspected that acute myocardial infarction in a patient with low cardiovascular risk and suspicious lung infiltration might be a presentation of Trousseau's syndrome.
INTRODUCTION
Trousseau's syndrome (TS) is most commonly defined as hypercoagulability and spontaneous thrombotic events associated with cancer. Pathogenesis of malignancy related coagulation disorder has not been completely elucidated, but is likely multifactorial and involves multiple mechanisms and interplaying pathways (1, 2). Trousseau's syndrome was initially described by French internist Armand Trousseau in 1860s (3), who, ominously coincidentally, recognized this foretelling sign of visceral malignancy in himself and soon after succumbed to a gastric cancer.
TS often precedes the diagnosis of occult or unrecognized visceral malignancy or it presents during the diagnosis of cancer. Underlying cancer was detected in almost 10% of patients with symptomatic idiopathic thromboembolism (4) . Cancers associated with TS are usually diagnosed in advanced stage, have poor prognosis and decreased survival, which may be linked to their aggressive biology (2, 5) .
TS comprises any kind of coagulopathy linked to malignant disease (2, 6, 7) . In clinical practice, TS is most frequently presented in a form of deep vein thromboses and subsequent thromboembolism, however arterial thrombotic events are not rare (7, 8) .
Concurrent venous and arterial thromboses may be triggered by stimuli that activate coagulation and inflammatory pathways in whole circulation system. Thrombotic events have the highest incidence in patients with lung cancer, probably due to high prevalence of pulmonary malignancy and its biological properties. Patients with non small cell lung cancer (NSCLC), especially adenocarcinoma, are at higher risk than those with small cell cancer histology (5, 9).
The effect of thrombotic events can be devastating in cancer patients: it may delay, hinder or preclude chemotherapy, decrease quality of life, increase health care and social burden and, as in herein described example, impose as a life threatening complication leading to death of the patient (1, 9).
Here we describe a rare case of TS presenting as acute myocardial infarction (AMI), associated with lung adenocarcinoma, which was diagnosed postmortem.
CASE REPORT
A 49-year-old man with abnormal 15mm shadow in right lung hilum on a chest X-ray was admitted to our hospital for diagnostic bronchoscopy. The patient had unremarkable medical and family history and was a non-smoker. He had no history of hypertension, coronary artery disease, hyperlipidemia, and use of illicit drugs. He reported significant weight loss during the last two months and occasional cough. Occlusive thrombi and thromboemboli were found in veins and arteries of medium and small caliber in visceral organs, and in venous plexuses of the pelvis. In the heart, blood clots formed predominantly of fibrin and in lesser extent of entrapped blood elements were found in medium and small coronary artery branches. This finding was prominent in the field of infarction, where necrosis of cardiomyocites was histologically obvious, but also in blood vessels of surrounding non-necrotic muscle. Verrucous thrombotic masses were found adhered to valvular endocardium of aortic valve. Pathohistological exam revealed that wedge shaped white-grayish fields found in left kidney and spleen represented coagulative necrosis, inflammatory infiltrate and stasis, consistent with recent ischemic infarction of these organs.
DISCUSSION
Trousseau's syndrome implies thrombotic problems that transpire in the setting of an occult or a recently diagnosed cancer and cannot be explained by any other obvious factor (1, 2). In a prospective randomized study of patients with idiopathic venous thromboembolism, an extensive screening for occult malignancy resulted in significantly reduced time to diagnosis and identification of cancer in an earlier stage (4). However, the impact of early detection of cancer on prognosis and quality of life remains unclear.
The frequency of thrombotic events among the patients with lung cancer is variable and influenced by numerous factors, but is generally higher in patients with NSCLC compared to SCLC, especially in those with adenocarcinoma histology. The incidence of VTE varies in patients with NSCLC, from 0% in early stage NSCLC to 7.9% in those with advanced disease who were treated with chemotherapy, and is fourfold higher in metastatic Patient with advanced lung adenocarcinoma, who developed non-bacterial thrombotic endocarditis, pulmonary embolism and low-grade disseminated intravascular coagulation was successfully treated with heparin and recombinant human soluble thrombomodulin, which enabled the patient to endure the following combination chemotherapy (6) . In present report, we found thrombotic formations on aortic valvular cusps which may be morphological presentation of marantic nonbacterial thrombotic endocarditis. Infarcts of the kidney and spleen probably developed as a consequence of tromboemboli that arose from these vegetations. Recently, spontaneous thrombosis of internal jugular vein has been described in patient with NSCLC (11). This supports the notion that TS can manifest as very diverse and polymorphic spectrum of thrombotic disorders associated with malignancy.
In a report describing AMI and ischemic stroke in patient with NSCLC, ischemic events were attributed to chemotherapeutic agent vinorelbine (12) . However, AMI in our Emerging evidence suggests that cancer associated thrombosis is caused by overexpression of tissue factor (TF) (1, 9, 17) . Thrombin generated in response to TF activates platelets and mediates further events in coagulation cascade, finally leading to fibrin deposition and clot formation. Moreover, TF and thrombin mediate various signaling pathways with a role in angiogenesis, tumor growth, cell migration and metastasis development. In cancer patients, TF is overexpressed by the tumor cells, and as a response of host tissues to inflammation and damage caused by tumor growth. TF elevation has been linked to reduced survival in many malignancies, including lung carcinoma (9, 17) . Recent study found that high levels of alternatively spliced TF, which lacks transmembrane domain and is thus solubile and present in circulation, have been associated with poor prognosis in NSCLC (18) .
Complex mechanisms of cancer coagulopathy may be genetically modulated by driver mutations that alter the expression of TF and other proteins involved in hemostasis (19) .
Activation of MET oncogene upregulates transcription of plasminogen activator inhibitor type1 (PAI-1), and cyclooxigenase-2, and both support thrombohaemorrhagic phenotype in vivo (20) . The EPICOR study identified PAI-1 as independent and common risk factor for cancer and ischemic cardiovascular disease, approximating the possible molecular link between mechanisms of thrombosis and tumorigenesis (21) . In addition, recent study identified K-RAS mutation as a driver of thromboembolic risk in NSCLC patients (22) .
Thrombotic events have negative impact on morbidity and mortality in cancer patients (5, 14) . Although there is no established medical protocol for managing Trousseau's syndrome in cancer patients, it has been suggested that intensive anticoagulant treatment may provide significant benefits. After AMI our patient was treated with warfarin ant antiaggregants, however intravascular thrombosis was not prevented. Treatment of thrombotic events in lung cancer patients is preferably conducted by low molecular weight
heparin, but therapy decision should be individualized (9, 23) . Timely and adequate therapy of coagulation disorders improves patients' condition, prevents possibly deadly thromboembolic complications and enables the patient to endure chemotherapy. Exclusively the reduction of tumor, usually achieved by chemotherapy, leads to resolution of Trousseau's syndrome.
In conclusion, although the relationship between malignancy and thrombotic events is well known, even suspected, undiagnosed cancer should urge the clinician to closely monitor the coagulation status of the patient and consider antithrombotic prophylaxis. Trousseau's syndrome is not rare, however the presentation with AMI is very seldom encountered in clinical practice. For patients without clinical evidence of atherosclerosis, hypercoagulability associated with cancer as underlying cause of AMI should be considered and investigated. 
